

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0104
Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* <u>Berg Aaron</u> (Last) (First) (Middle) <u>C/O AMARIN PHARMA, INC.</u> <u>1430 ROUTE 206</u> (Street) <u>BEDMINSTER NJ</u> <u>07921</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>03/11/2019</u>	3. Issuer Name and Ticker or Trading Symbol <u>AMARIN CORP PLC\UK [AMRN]</u>	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>CHIEF COMMERCIAL OFFICER</u>	5. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
--	--	---	--	--	---

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Ordinary Shares⁽¹⁾</u>	<u>36,351</u>	<u>D</u>	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Restricted Stock Units⁽²⁾</u>	<u>(3)</u>	<u>(4)</u>	<u>Ordinary Shares⁽¹⁾</u>	<u>29,000</u>	<u>0.00</u>	<u>D</u>	
<u>Restricted Stock Units⁽²⁾</u>	<u>(5)</u>	<u>(4)</u>	<u>Ordinary Shares⁽¹⁾</u>	<u>78,000</u>	<u>0.00</u>	<u>D</u>	
<u>Restricted Stock Units⁽²⁾</u>	<u>(6)</u>	<u>(4)</u>	<u>Ordinary Shares⁽¹⁾</u>	<u>38,200</u>	<u>0.00</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>(7)</u>	<u>12/02/2022</u>	<u>Ordinary Shares⁽¹⁾</u>	<u>43,253</u>	<u>12.6</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>(8)</u>	<u>02/02/2025</u>	<u>Ordinary Shares⁽¹⁾</u>	<u>3,906</u>	<u>1.02</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>(9)</u>	<u>07/06/2025</u>	<u>Ordinary Shares⁽¹⁾</u>	<u>219,562</u>	<u>2.5</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>(10)</u>	<u>02/01/2026</u>	<u>Ordinary Shares⁽¹⁾</u>	<u>36,458</u>	<u>1.4</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>(11)</u>	<u>02/01/2027</u>	<u>Ordinary Shares⁽¹⁾</u>	<u>69,270</u>	<u>2.95</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>(12)</u>	<u>05/01/2028</u>	<u>Ordinary Shares⁽¹⁾</u>	<u>117,000</u>	<u>2.8</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>(13)</u>	<u>02/01/2029</u>	<u>Ordinary Shares⁽¹⁾</u>	<u>53,500</u>	<u>16.87</u>	<u>D</u>	

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion.
3. On February 1, 2017, the Reporting Person was granted 87,000 RSUs under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in three equal installments on each of January 31, 2018, January 31, 2019, and January 31, 2020.
4. Not applicable.
5. On May 1, 2018, the Reporting Person was granted 78,000 RSUs under the Plan. These RSUs vest in three equal installments on each of May 1, 2019, May 1, 2020, and May 1, 2021.
6. On February 1, 2019, the Reporting Person was granted 38,200 RSUs under the Plan. These RSUs vest in three equal installments on each of January 31, 2020, January 31, 2021, and January 31, 2022.
7. On December 3, 2012, the Reporting Person was granted an option to purchase 75,000 Ordinary Shares under the Plan. The shares subject to this option are fully vested as of the date hereof.
8. On February 2, 2015, the Reporting Person was granted an option to purchase 93,750 Ordinary Shares under the Plan. The shares subject to this option are fully vested as of the date hereof.
9. On July 6, 2015, the Reporting Person was granted an option to purchase 400,000 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments on the last day of each month that began on July 31, 2015.
10. On February 1, 2016, the Reporting Person was granted an option to purchase 125,000 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments on the last day of each month that began on February 28, 2016.
11. On February 1, 2017, the Reporting Person was granted an option to purchase 133,000 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments on the last day of each month that began on February 28, 2017.
12. On May 1, 2018, the Reporting Person was granted an option to purchase 117,000 Ordinary Shares under the Plan. The shares subject to this option shall vest as follows: 25% of the total number of underlying shares shall vest on May 1, 2019, and the remaining 75% of the underlying shares shall vest ratably over the subsequent 36 months.
13. On February 1, 2019, the Reporting Person was granted an option to purchase 53,500 Ordinary Shares under the Plan. The shares subject to this option shall vest and become exercisable in 16 equal quarterly installments starting on May 15, 2019.

Remarks:

Pursuant to Amarin's expanded commercial efforts, the company's Board of Directors has deemed Aaron Berg to be an executive officer in accordance with Section 16.

/s/ Joseph Kennedy, by power 03/20/2019

[of attorney](#)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY
For Executing Forms 3, 4 and 5

Know all by these presents, that the undersigned hereby constitutes and appoints each of John F. Thero, Joseph T. Kennedy and Michael W. Kalb, each acting singly, his true and lawful attorney-in-fact from the date hereof to:

(1) Execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of Amarin Corporation plc (the "Company"), forms and authentication documents for EDGAR Filing Access;

(2) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(3) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete the execution of any such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and the timely filing of such form with the United States Securities and Exchange Commission and any other authority; and

(4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interests of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary, and proper to be done in the exercise of any of the rights and powers herein granted, as fully for all intents and purposes as the such attorney-in-fact might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or his substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

By this Power of Attorney, the undersigned further revokes all previous powers of attorney relating to the undersigned's obligations to file Forms 3, 4 and 5 in respect of the Company's securities under Section 16(a) of the Securities Exchange Act of 1934 and related matters.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 8th day of March, 2019.

/s/ Aaron Berg

Aaron Berg